Voxamin XR-150 Extended Release Capsule

About Voxamin XR-150 Extended Release Capsule

Voxamin XR-150 is an extended release capsule made by Renata PLC. It contains fluvoxamine maleate 150 mg, a medicine that raises serotonin activity in the brain and is used for certain mental health conditions.

There are 4 brands of Fluvoxamine Maleate listed in Bangladesh.

What is Voxamin XR-150 Extended Release Capsule?

Voxamin XR-150 is an extended release capsule containing fluvoxamine maleate 150 mg. It belongs to the SSRI group of antidepressants. It works by reducing the reabsorption of serotonin in the brain, which raises serotonin activity; the exact way it acts is not fully understood. Doctors prescribe this kind of medicine for obsessive-compulsive disorder and depressive illness, and it may also be used in panic disorder, eating disorders and chronic tension headache. The dose and course are decided by the doctor.

Uses of Voxamin XR-150

Voxamin XR-150 is used for obsessive-compulsive disorder and depressive illness. It may also be prescribed for panic disorder, eating disorders and chronic tension headache. It is not a quick fix and relief usually comes with continued medical follow-up. Do not change or stop the medicine on your own; ask your doctor if you have questions about your treatment.

How to use Voxamin XR-150

Take Voxamin XR-150 exactly as your doctor tells you. The doctor decides the dose, the timing and how long you take it, and the dose may be adjusted over time. Swallow the extended release capsule as directed by your doctor or pharmacist; do not chew or crush it unless told to. If you miss a dose, ask your doctor or pharmacist what to do. Do not stop suddenly without medical advice.

Side effects of Voxamin XR-150

Common side effects reported with this type of medicine include nausea, drowsiness, trouble sleeping, weakness, nervousness, indigestion, sweating, reduced appetite, tremor and vomiting. Some people report dry mouth, changes in sexual function and urinary frequency. Many side effects settle with time. Tell your doctor about any side effect that bothers you or does not go away, and seek medical help for severe or unusual reactions.

Safety and precautions

Talk to your doctor before using Voxamin XR-150 if you have a history of mania, seizures, suicidal thoughts, heart disease, diabetes, angle-closure glaucoma, bleeding problems, or liver or kidney problems. It may affect driving and skilled tasks. It must not be combined with certain other medicines. Tell your doctor if you are pregnant, planning pregnancy or breastfeeding, because risks and benefits need to be weighed. Your doctor or pharmacist should be asked about any concern before you start.

Frequently asked questions

What kind of medicine is Voxamin XR-150 and what is it used for?

It is an SSRI antidepressant containing fluvoxamine maleate 150 mg in an extended release capsule. It is used for obsessive-compulsive disorder and depressive illness, and may also be prescribed for panic disorder, eating disorders and chronic tension headache. Your doctor will confirm whether it suits your condition.

Which medicines may interact with Voxamin XR-150?

It can interact with several other medicines, including carbamazepine, sumatriptan, tacrine and tricyclic antidepressants, and it must not be combined with some medicines such as tizanidine, thioridazine, alosetron and pimozide. Tell your doctor and pharmacist about everything you take, including other medicines, before starting.

How should I take Voxamin XR-150?

Take it exactly as your doctor directs. The doctor decides the dose, timing and length of treatment, and may adjust the dose over time. Swallow the extended release capsule as advised and do not stop the medicine suddenly. Ask your doctor or pharmacist if you are unsure or miss a dose.

What should I tell my doctor before starting Voxamin XR-150?

Tell your doctor about any history of mania, seizures, suicidal thoughts, heart, liver or kidney problems, diabetes, glaucoma or bleeding disorders, and about pregnancy or breastfeeding. Also mention all other medicines you take. Your doctor will decide whether this medicine is suitable for you.

Indications

Maprotiline Hydrochloride is indicated in-
  • Obsessive-Compulsive Disorder
  • Depressive illness
  • Panic Disorder
  • Eating Disorders
  • Chronic Tension Headache

Pharmacology

The exact mechanism of action of fluvoxamine has not been fully determined but appears to be linked to its inhibition of CNS neuronal uptake of serotonin. Fluvoxamine blocks the reuptake of serotonin at the serotonin reuptake pump of the neuronal membrane, enhancing the actions of serotonin on 5HT1A autoreceptors. Studies have also demonstrated that fluvoxamine has virtually no affinity for α1- or α2-adrenergic, β-adrenergic, muscarinic, dopamine D2, histamine H1, GABA-benzodiazepine, opiate, 5-HT1, or 5-HT2 receptors, despite having an affinity for binding to σ1 receptors.

Dosage & Administration

Adults: The recommended starting dose for Fluvoxamine Maleate Tablets in adult patients is 50 mg, administered as a single daily dose at bedtime. In the controlled clinical trials establishing the effectiveness of Fluvoxamine Maleate Tablets in OCD, patients were titrated within a dose range of 100 to 300 mg/day. Consequently, the dose should be increased in 50 mg increments every 4 to 7 days, as tolerated, until the maximum therapeutic benefit is achieved, not to exceed 300 mg per day. It is advisable that a total daily dose of more than 100 mg should be given in two divided doses. If the doses are not equal, the larger dose should be given at bedtime.

Pediatric Population (children and adolescents): The recommended starting dose for Fluvoxamine Maleate Tablets in pediatric populations (ages 8-17 years) is 25 mg, administered as a single daily dose at bedtime. In a controlled clinical trial establishing the effectiveness of Fluvoxamine Maleate Tablets in OCD, pediatric patients (ages 8-17) were titrated within a dose range of 50 to 200 mg/day. Physicians should consider age and gender differences when dosing pediatric patients. The maximum dose in children up to age 11 should not exceed 200 mg/day. Therapeutic effects in female children may be achieved with lower doses. Dose adjustment in adolescents (up to the adult maximum dose of 300 mg) may be indicated to achieve therapeutic benefit. The dose should be increased in 25 mg increments every 4 to 7 days, as tolerated until the maximum therapeutic benefit is achieved. It is advisable that a total daily dose of more than 50 mg should be given in two divided doses. If the two divided doses are not equal, the larger dose should be given at bedtime.

Elderly or Hepatically Impaired Patients: Elderly patients and those with hepatic impairment have been observed to have a decreased clearance of fluvoxamine maleate. Consequently, it may be appropriate to modify the initial dose and the subsequent dose titration for these patient groups.

Interaction

Drugs Inhibiting or Metabolized by Cytochrome P450: Fluvoxamine inhibits several cytochrome P450 isoenzymes (CYP1A2, CYP2C9, CYP3A4, and CYP2C19).

Carbamazepine: Elevated carbamazepine levels and symptoms of toxicity with coadministration (7.2).

Sumatriptan: Rare postmarketing reports of weakness, hyperreflexia, and incoordination following use of an SSRI and sumatriptan. Monitor appropriately if concomitant treatment is clinically warranted.

Tacrine: Coadministration increased tacrine C max and AUC five- and eight-fold and caused nausea, vomiting, sweating, and diarrhea.

Tricyclic Antidepressants (TCAs): Coadministration significantly increased plasma TCA levels. Use caution; monitor plasma TCA levels; reduce TCA dose if indicated.

Tryptophan: Severe vomiting with coadministration.

Diltiazem: Bradycardia with coadministration.

Propranolol or metoprolol: Reduce dose if coadministered and titrate more cautiously

Contraindications

Coadministration of tizanidine, thioridazine, alosetron, pimozide.

Serotonin Syndrome and MAOIs: Do not use MAOIs intended to treat psychiatric disorders with Fluvoxamine Maleate Tablets or within 14 days of stopping treatment with Fluvoxamine Maleate Tablets. Do not use
Fluvoxamine Maleate Tablets within 14 days of stopping an MAOI intended to treat psychiatric disorders. In addition, do not start Fluvoxamine Maleate Tablets in a patient who is being treated with linezolid or intravenous methylene blue.

Side Effects

Most common reactions in controlled trials with adult OCD and depression patients (incidence ≥5% and at least twice that for placebo) were nausea, somnolence, insomnia, asthenia, nervousness, dyspepsia, abnormal ejaculation, sweating, anorexia, tremor, and vomiting. Using the above rule, the following events were also identified: anorgasmia, decreased libido, dry mouth, rhinitis, taste perversion, and urinary frequency in patients with OCD; and agitation, depression, dysmenorrhea, flatulence, hyperkinesia, and rash in pediatric patients with OCD.

Pregnancy & Lactation

Consider both potential risks and benefits when treating a pregnant woman. Infants exposed to SSRIs late in pregnancy have developed various complications and may be at risk for persistent pulmonary hypertension of the newborn (PPHN). Fluvoxamine is secreted in human breast milk.

Precautions & Warnings

Fluvoxamine Maleate should be used with caution in patients with a history of mania, seizures, suicide, concomitant ECT, cardiac disease, diabetes mellitus, angle-closure glaucoma, history of bleeding disorders (especially gastrointestinal bleeding), hepatic and renal impairment. Fluvoxamine maleate may also impair the performance of skilled tasks (driving).

Storage Conditions

Keep below 30°C temperature, away from light & moisture. Keep out of the reach of children.

Alternative brands of Fluvoxamine Maleate

Other brands with the same generic name, cheapest first.

Medicine information is for reference only and is not medical advice. Always follow your doctor's prescription and check with a pharmacist.